

6.1.2 Antimicrobial Stewardship

Intervention Type	4 th Q23	1 st Q24	2 nd Q24	3 rd Q24	12 Month Total
De-escalation	315	330	393	367	1,405
Dose adjustment	2,995	3,062	3,072	2,922	12,051
Bug-Drug mismatch	142	137	121	118	518
IV to PO conversion	582	548	608	652	2,390
Therapeutic duplication	100	111	91	86	388
Totals	4,134	4,188	4,285	4,145	16,752

QUALITY IMPROVEMENT

- The NHSN Antimicrobial Use (AU) and Antimicrobial Resistance (AR) (AUR) Module reporting to CMS. Interoperability reporting required by 2024

OTHER

- Tetanus vaccine formulary review (TD removal)
- COVID medication restriction criteria (Baricitinib, Tocilizumab, Remdesivir)
- Amikacin for *Acinetobacter baumannii* Complex - reporting upon request
- Clindamycin reporting for β -hemolytic *Streptococci* – report susceptibility on all Group A Strep except for throat or urine cultures